<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412191</url>
  </required_header>
  <id_info>
    <org_study_id>LAM105379</org_study_id>
    <nct_id>NCT00412191</nct_id>
  </id_info>
  <brief_title>Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR</brief_title>
  <official_title>A Pivotal Single-dose Randomised, Parallel-group, Open-label Study to Demonstrate Bioequivalence of 300mg Lamotrigine XR Relative to 100mg + 200mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 300mg Lamotrigine XR in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to demonstrate bioequivalence and lack of food effect on 300mg lamotrigine
      XR in healthy male and female volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2007</start_date>
  <completion_date type="Actual">April 27, 2007</completion_date>
  <primary_completion_date type="Actual">April 27, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics ie Serum lamotrigine Cmax and AUC(0-inf)</measure>
    <time_frame>taken pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 36, 48, 72, 96, 120 and 144 hours following dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK (AUC (0-t), tmax and t1/2 )</measure>
    <time_frame>taken pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 36, 48, 72, 96, 120 and 144 hours following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability based on physical exam, adverse events, changes in biochemistry, haematology, urinalysis parameters, electrocardiogram parameters, blood pressure and heart rate measure</measure>
    <time_frame>at Screening, Day -1, Day 1, Day 2 and follow up 7-14 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Subjects in treatment regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in treatment regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in treatment regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.</description>
    <arm_group_label>Subjects in treatment regimen B</arm_group_label>
    <arm_group_label>Subjects in treatment regimen C</arm_group_label>
    <arm_group_label>Subjects in treatment regimen A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt;50 kg (males) or &gt;45 kg (females) and BMI within the range 19 - 29.9
             kg/m2 inclusive.

          -  Healthy as determined by a responsible physician, based on a medical evaluation
             including history, physical examination, laboratory tests, vital signs and ECG. A
             subject with a clinical abnormality or laboratory parameters outside the reference
             range for the population being studied may be included only if the Investigator
             considers that the finding will not introduce additional risk factors and will not
             interfere with the study procedures.

        Exclusion Criteria:

          -  Female subjects of childbearing potential will not be eligible to participate who are
             unwilling or unable to use an appropriate method of contraception as outlined in the
             inclusion criteria from at least the commencement of their last normal period prior to
             the first dose of study medication; and to continue until the first normal period
             (defined as normal for the woman, both in terms of duration and quantity of menses)
             after treatment or 5 half lives of the study medication, whichever is the longest.

          -  Female subject is pregnant (positive serum human chorionic gonadotrophin (hCG) test at
             screening) or lactating.

          -  Female subjects using hormonal contraceptive precautions including progesterone-coated
             IUD

          -  Female subjects using hormonal replacement therapy.

          -  Subjects who received lamotrigine in a previous study (subjects who received placebo
             will be allowed).

          -  Current smokers of 10 or more cigarettes per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/LAM105379?search=study&amp;search_terms=LAM105379#rs</url>
    <description>Results for study LAM105379 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>This study has not been published in the scientific literature.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>food effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LAM105379</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

